DDrare: Database of Drug Development for Rare Diseases

Oms721 (narsoplimab) (DrugBank: Narsoplimab)

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
66	IgA腎症	1
222	一次性ネフローゼ症候群	1
223	一次性膜性増殖性糸球体腎炎	1

66. IgA腎症　［臨床試験数：199，薬物数：214（DrugBank：57），標的遺伝子数：32，標的パスウェイ数：128］

Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 199 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02682407 (ClinicalTrials.gov)	February 2016	10/2/2016	Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721	A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease	IgAN;Lupus Nephritis;MN;C3 Glomerulopathy	Biological: OMS721 (narsoplimab)	Omeros Corporation	NULL	Recruiting	18 Years	N/A	All	54	Phase 2	United States;Hong Kong

222. 一次性ネフローゼ症候群　［臨床試験数：234，薬物数：241（DrugBank：78），標的遺伝子数：59，標的パスウェイ数：185］

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 234 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02682407 (ClinicalTrials.gov)	February 2016	10/2/2016	Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721	A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease	IgAN;Lupus Nephritis;MN;C3 Glomerulopathy	Biological: OMS721 (narsoplimab)	Omeros Corporation	NULL	Recruiting	18 Years	N/A	All	54	Phase 2	United States;Hong Kong

223. 一次性膜性増殖性糸球体腎炎　［臨床試験数：18，薬物数：14（DrugBank：7），標的遺伝子数：7，標的パスウェイ数：14］

Searched query = "Primary membranoproliferative glomerulonephritis", "Dense deposit disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 18 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02682407 (ClinicalTrials.gov)	February 2016	10/2/2016	Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721	A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease	IgAN;Lupus Nephritis;MN;C3 Glomerulopathy	Biological: OMS721 (narsoplimab)	Omeros Corporation	NULL	Recruiting	18 Years	N/A	All	54	Phase 2	United States;Hong Kong